Multipurpose solution for epibulbar instillations

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology and clinical pharmacy, and is applicable for visual organ and facial skin sanitation in purulent conjunctivitis, eyelid adhesion and dacryolith formation. The invention consists in the fact that an agent represents an antiseptic water solution consisting of 0.55-1.0 % hydrogen peroxide, 1.0-1.5 % sodium hydrocarbonate and 0.5-1.0 % lidocaine hydrochloride.

EFFECT: invention provides effective and safe conditions for the conjunctival cavity, eyelash, eyelid, surrounding face sanitation.

1 ex

 

The invention relates to medicine, in particular to ophthalmology and clinical pharmacy, and can be used for dilution and removal of thick pus and tear stones from the conjunctival cavity, eyelids, eyelid skin and face around the eye with conjunctivitis.

Known remedy for thinning thick and sticky pus, which is an aqueous solution of 3±0.3% of hydrogen peroxide and 5-10% sodium bicarbonate (EN 2360685).

A disadvantage of the known tool is the narrow scope of application, low efficiency and safety, because the drug has extremely high physical-chemical and biological aggressiveness and local toxicity due to the presence of high concentrations of hydrogen peroxide (3±0,3%), which provides watering and excessive physical-chemical aggressiveness due to violent gassing in purulent environment. Therefore, the instillation of even one drop of such funds in the eye slit immediately causes burning sensations, blepharospasm, rapid blinking of the eyelids and spasm of accommodation. When conjunctivitis is a rapid foaming of a liquid medium in a closed conjunctival cavity, as immediately after putting funds in the eye slit she reflexively closed for the coming of blepharospasm and reflex dense compression century. Arr is soumise in a closed conjunctival cavity gaseous oxygen explodes this cavity, increases the inside pressure, opens the eyelids, eye opens a crack and breaks through it out together with the liquid content. Departing out gaseous oxygen "captures" together with a liquid medium and splashes (scatters) the fragments of purulent masses, which are emitted from the palpebral fissure with a high speed at a distance of about 1 m So well-known drug does not protect the eye from irritation, while he himself advanced annoying him, because with the introduction of purulent conjunctival cavity causes a rapid expansion of purulent environment and irritation of inflamed conjunctiva quickly moving on its surface purulent fragments and gas bubbles. In addition, the process of spraying pus from the eye staining clothes and the environment that promotes infection conjunctivitis people who are close by, and leads to the spread of infection.

In addition, the presence in solution of sodium bicarbonate at a concentration of 5-10% increases the osmotic activity of the solution to values 940-1880 mosmol/l of water. This hyperosmotic activity of the solution gives it additional physico-chemical aggression in relation to living tissue due to the pronounced dehydrating steps, which further reduces security because of the possibility of dehydration damage epitelio itow and burns of the mucous membrane of the organ of vision.

Known eye drops for the treatment of dry eye syndrome on the basis of phospholipid in physiological solution of sodium salts, including sialic (karamanova) acid, L-carnosine and sodium salts of sulfated glycosaminoglycans of createsurface and chondroitin sulphate at a certain ratio of components (EN 2302231 C1).

A disadvantage of the known tool is the narrow scope of application, low efficiency and safety, because the drug has a high biological aggressiveness (in particular, due to hyperallergenic) and has a tear action. In addition, a well-known tool does not possess local anaesthetic, anti-inflammatory, politicheskoi (heerassagala), camerastore and antiseptic activity. Moreover, the drug contributes to the stabilization of dense aggregate state of the lacrimal stones and purulent masses by reducing the evaporation of moisture.

Known eye drops, which is an aqueous solution of 2% and 4% lidocaine hydrochloride with the addition of 1 drop of 0.1% solution of epinephrine hydrochloride to 5-10 ml of lidocaine hydrochloride (Mashkovsky PPM Medicines. 2 so That 1 (14th edition). M: The New Wave. 2000. S-295).

A disadvantage of the known tool is the narrow scope of application, low efficiency and safety, since p is apart has a high local toxicity, has no politicheskoi (heerassagala), camerastore, and sanative antiseptic activity. High local toxicity caused by high concentration of lidocaine hydrochloride, Allergy, as well as the presence of another highly toxic drugs - epinephrine hydrochloride. In addition, the known solution of a medicinal product has no alkalinity, buffering capacity and therefore does not have sufficient washing and sanitizing activity.

The objective of the invention is the extension of the scope, efficiency and safety by reducing physical, chemical and biological aggressiveness and local toxicity.

This objective is achieved in that the multifunctional solution for epibulbar instillation, which is an aqueous solution of hydrogen peroxide, sodium bicarbonate and lidocaine hydrochloride, provides them with the following ratios, wt.%:

The peroxide0,55-1,0
Sodium bicarbonate1,0-1,5
Lidocaine hydrochloride0,5-1,0
Water for injection Rest

The essence of the proposed multifunctional solution for epibulbar instillation, which is an aqueous solution of hydrogen peroxide, sodium bicarbonate and lidocaine hydrochloride, is that they are in the following ratio, wt.%:

The peroxide0,55-1,0
Sodium bicarbonate1,0-1,5
Lidocaine hydrochloride0,5-1,0
Water for injectionRest

The presence of a water solution of hydrogen peroxide at a concentration of 0.55 to 1.0% provides low physico-chemical and biological aggressiveness low local toxicity to living tissues of the organ of vision while maintaining the ability to thin thick purulent mass in the conjunctival cavity in both open and closed eye slits when batting eyelids due to the upcoming reflex blepharospasm. The fact that increasing the concentration of hydrogen peroxide than 1.0% in solution with sodium bicarbonate enhances foaming activity to excessively high values, capable in the throw of the palpebral fissure in the form of a spray out as the solution itself, and purulent mass. In this case, there is the danger of irritation of the mucous membrane of the conjunctival cavity. On the other hand, low concentrations of hydrogen peroxide below 0,55% reduces heerassagala activity of the solution, and it does not dilute purulent mass at body temperature for a period of less than 10 seconds of interaction. The ability to thin thick pus for a longer duration of direct interaction of eye drops with pus does not increase the efficiency of restoration of the organ of vision in purulent conjunctivitis with eye drops. The fact that the eye drops when used in their inflamed eye with purulent conjunctivitis are palpebral fissure no longer than 6 seconds, because that is how much continues blepharospasm. After the termination of blepharospasm, a period of rapid blinking of the eyelids and medicine in seconds is removed outside the flow of lacrimal fluid and high "cleaned" activity age due to increased watery eyes and frequent blinking of the eyelids, emerging with the advent of the burning feeling in the eye.

The presence in solution of sodium bicarbonate at a concentration of 1.0 to 1.5% provides a stable measure of the basicity of the solution to about pH 8.0 at low physico-chemical and biological aggressiveness towards living tissues of the organ of vision, low local toxicity and the high politicheskoi activity. In particular, the presence of sodium bicarbonate at a concentration of 1.0 to 1.5% provides:

- low physico-chemical and biological aggressiveness and local toxicity of the solution and its interaction with the mucosa of organ of vision due to praiseworthy solution

- high speed and efficiency of the thin surface layer of thick pus due to the high wetting, penetrating and amylase activity mortar,

- high speed, efficiency and security otkleivanie" tear stones from the skin of the eyelids and eyelashes due to the high penetration", amylase, politicheskoi and solvent activity of the drug, which is due to the potentially high zaschelachivayuschie and surface activity of the solution in combination with sufficient buffering,

- high security and the efficiency of removal of the tear stones and fragments of thick pus (washing, laundering, cleansing them from the skin and eyelashes) due to the high wetting and surface activity of the solution

- high efficiency of dissolution of the lacrimal stones due to the high amylase, wetting and surface activity of the solution.

While specified zaschelachivayuschie, malausa, wetting, dissolving, washing, surface activity of the solution in the specified range of concentrations of sodium GI is recarbonate provides dilution purulent masses and the dissolution of the lacrimal stones without damaging the lashes, skin of eyelids and face and mucous membranes of the organ of vision.

Increasing the concentration of sodium bicarbonate is higher than 1.5% at body temperature begins to give the solution of annoying activity, and lowering the concentration of sodium bicarbonate is less than 1.0% reduces the ability of a solution to thin thick pus and dissolve the lacrimal stones directly proportional to the rate of change of concentration.

The presence in the solution of the local anesthetic lidocaine hydrochloride in a concentration of 0.5-1.0% provides the instillation in the eye slit is effective local anesthesia inflamed organ of vision when conjunctivitis, reduces lacrimation, blepharospasm, hyperthermia, flushing, swelling and tenderness of the inflamed organ of vision, and also eliminates tear the action of hydrogen peroxide.

Increasing the concentration of lidocaine hydrochloride than 1.0% insignificant increases above local pharmacological activity of the drug, but increases local toxicity and gives dwuhfaznosti local action, namely after insertion in the eye initially causes short-term (within 3-5 seconds) irritation of the eyes and the appearance of symptoms of reactive inflammation, i.e. conjunctivitis. Low concentrations of lidocaine hydrochloride below 0.5% slows surface anesthesia and reduction of symptoms is conjunctivitis is directly proportional to the degree of decrease in concentration.

The instillation in the eye slit of a multifunctional solution for epibulbar instillation and when washing (wiping) of the eyelashes, eyelids and face around the body of view this solution, the following changes occur. The presence in solution of lidocaine hydrochloride provides effective and fast wetted surface anesthesia of the skin and mucous membranes, reduction of all symptoms of conjunctivitis prevention and tear action of hydrogen peroxide. The presence of sodium bicarbonate provides the alkalization and liquefaction surface purulent masses and tear stones at their wetting solution due to the high penetrating, wetting, amylase, washing, solvent (crystals of salts of alkali metals), as well as solvent and vasospasm (crystals and dense colloidal mass of protein) activity. The presence of hydrogen peroxide provides for interaction with purulent mass release of molecular oxygen, the formation of gas bubbles on the surface and in the thickness of purulent masses, which breaks down and liquefies thick purulent masses, suspenseful, platinum solution (by flushing), and provides high efficiency sanitize all hard to reach areas conjunctival cavity, eyelashes, eyelids and face around the organ of vision.

The application of the lidocaine solution guide is ochloride, sodium bicarbonate and hydrogen peroxide in the form of instillation 1-2 drops into the conjunctival opening and wetting eyelashes, eyelids and face around the eye leads to rapid penetration of the solution into purulent masses and tear stones due to the diffusion in the surface. Thus there is "alkaline" penetration into the surface, "hydrogen peroxide" its destruction due to interstitial cold "boil", "local anaesthetic" eliminating irritating and lacrimating steps of the solution and reducing the symptoms of conjunctivitis and painless removal of eye pus and tear stones.

Example. Patient T., 32 years appealed to the Cabinet emergency eye hospital with complaints of feeling a strong burning sensation, tearing, photophobia and blepharospasm right eye that occurred after accidental exposure to tear gas and subsequent rubbing his eyes dirty fingers. During the inspection confirmed the presence of right-purulent conjunctivitis, over which the eye slit of the right eye during the inspection were entered 2 drops of a solution of 20% sulfatsila sodium. However, the introduction of this drug immediately called blepharospasm duration 6 seconds, increased lacrimation and subsequent increased frequency of blinking of the eyelids for 30 seconds. Due to the persistent burning sensation in the right eye and arising in a patient with fear before instillation into the patient's eyes tear eye drops patient were prescribed eye drops, consisting of a solution of 4% lidocaine hydrochloride with the addition thereto of a solution of 0.1% epinephrine hydrochloride (1 drop of 0.1% solution of epinephrine hydrochloride in 5 ml of lidocaine hydrochloride), 1 drop in the right conjunctival cavity 3 times a day. After 2 days, the patient contacted the office of emergency eye clinic again because lacrimation, photophobia, and geobrowse in his right eye has not decreased, moreover, moved to the left eye. Moreover, the patient complained of "bonding" of the eyelids in the morning and the emergence of the lacrimal stones in the corners of the eyes and at the edges of the eyelids. During the inspection it was noted the presence of thick pus in both eyes and was diagnosed with bilateral purulent conjunctivitis. In the Cabinet for removal of thick pus from the eye was introduced in each eye one drop of a solution of 3% hydrogen peroxide and 5% sodium bicarbonate. However, the introduction of these tools has increased the burning sensation in the eyes, caused blepharospasm duration of 10 seconds, increased lacrimation and increased frequency of blinking of the eyelids.

In this regard, a well-known tool has been cancelled and for treatment was applied to the developed multifunctional solution (which is an aqueous solution of 0.55% hydrogen peroxide, 1% sodium bicarbonate and 0.5% lidocaine hydrochloride) for epibulbar instillation. This solution was appointed as the introduction is of his drops in both eyes 2 drops 3-5 times a day, and in the morning prior rubbing his eyes with a cloth moistened with this solution. In terms of the Cabinet emergency first application of the above solution was carried out by medical personnel. It turned out that conducted the first wiping his eyes with a cloth moistened with this solution, led to a complete cleansing of the eyelashes, eyelids and face around the eyes from crusts dried pus and pieces of eye stones, and the subsequent introduction of the developed solution in both eyes 2 drops in terms of the Cabinet emergency led in a few minutes to achieve politicheskogo, anti-inflammatory and analgesic effects. When viewed "stained" cloth after wiping her eyes on her dirty (stained) surface were found "melted" the remains of the lacrimal stones and diluted fragments of thick pus. Subsequent daily use of this tool has led to a gradual recovery. The next day the symptoms of purulent conjunctivitis began to decrease, in particular, has disappeared lacrimation and photophobia. Through the day in addition disappeared pus. This solution was used for the renovation of the eye 5 times per day for 3 consecutive days. On the 3rd day completely disappeared pain, hyperthermia, flushing, edema of the eyelids, sclera and conjunctiva, and functioning of the social indicators of the organs of vision are normal. Therefore, the treatment was stopped.

Therefore, this tool increases efficiency and safety by reducing physical, chemical and biological aggressiveness and local toxicity. In addition, the claimed tool extends the scope of applicability, as it ensures the destruction of the lacrimal stones and washing eyelashes and eyelid skin and face around the eye with purulent conjunctivitis and bonding century.

The invention provides for the extension of the scope, efficiency and safety by reducing physical, chemical and biological aggressiveness and local toxicity of the solution with optimal alkaline hydrolytic and mechanical destructive ability in relation to thick and dry dense masses.

Multifunctional solution for epibulbar instillation, hydrogen peroxide, sodium bicarbonate, lidocaine hydrochloride, and water, characterized in that they are in the following ratio, wt.%:

The peroxide0,55-1,0
Sodium bicarbonate1,0-1,5
Lidocaine hydrochloride0,5-1,0
Water is La injections Rest



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to ophthalmology. An ophthalmic device comprises a polymer matrix which in turn contains a biologically active agent and a carrier. The ophthalmic device is applicable for release of the biologically active agent induced by one or more amounts of lachrymal components from the polymer matrix in contact with tears in an eye. A method for making the ophthalmic device involves mixing a matrix-forming substance, the carrier and the biologically active agent, introducing a mixture into a cast for making the device and polymerising the matrix-forming substance in the cast. A method for biologically active agent delivery to a subject involves subject's eye contact with the device wherein one or more amounts of the lachrymal components release the biologically active agent from the device.

EFFECT: invention provides the stable ophthalmic device which is effective to deliver the biologically active agents into patient's eyes for long periods of time.

19 cl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to ophthalmology. A drug preparation stimulates proliferation of epithelial cells of a tarsal gland or epithelial cells of a cornea. The drug preparation contains [3-[2-[4-isopropyl-2-(4-triflouromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-triflouromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chloriophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy] acetic acid, or their pharmaceutically acceptable salt as an active ingredient. Said active ingredient is applied for making the drug preparation, and as stimulating proliferation of epithelial cells of the tarsal gland or epithelial cells of the cornea.

EFFECT: group of inventions provides treating eye diseases, such as xerophthalmus, tarsal gland dysfunction, corneal epithelial diseases.

18 cl, 3 dwg, 4 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used to treating spastic squint and atypincal squint accompanying type 1 Duane syndrome. It involves exposing a lateral end of an internal rectus muscle, further at 2-3 mm from an attachment point of the muscle to sclera a needle is inserted in an end face of the lateral muscle; the needle is moved at 8-10 mm along the muscle in a distal direction at an angle from the lateral end of the muscle to its middle axial border, and the preparation Disport 15-20 units is introduced. The incisional wound is closed. The similar method is used for surgical manipulations on the internal rectus muscle of the other eye, if the patient suffers from spastic squint and double Duane syndrome.

EFFECT: method provides reduced dynamometric functions of the internal rectus muscles and compensated optimal balance in the oculogyric system.

2 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula I or their pharmaceutically acceptable salts showing an ability to inhibit sphingosine kinase, to a based pharmaceutical composition, to a method of inhibiting sphingosine kinase and a method of treating diseases specified in breast cancer, diabetic retinopathy, arthritis and colitis. , wherein X represents -C(R3,R4)N(R5)-, -C(O)N(R4)-; R1 represents phenyl unsubstituted or substituted by 1 or 2 halogens. The values of R2, R3, R4, R5 substitutes are such as specified in the patent claim.

EFFECT: preparation of new compounds.

17 cl, 24 dwg, 9 tbl, 26 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely ophthalmology, and may be used for treating dry eye syndrome and recovered function of lachrymal fluid secretion in a mammal. For this purpose, a composition containing a pharmaceutically effective amount of a Janus kinase 3 inhibitor of the following structure is introduced in a mammal: 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d] pyrimidin-4-yl) amino] piperidin-1-yl}-3-oxopropionitryl.

EFFECT: introduction of the Janus kinase 3 inhibitor enables considerable increase of the secreted lachrymal fluid volume.

11 cl, 2 tbl, 6 ex, 8 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology, and can be used for ensuring regression of ocular neovascularisation. That is ensured by introducing a composition containing a therapeutically effective amount of a receptor tyrosine kinase inhibitor which blocks tyrosine autophosphorylation of VEGF receptor-2 with IC50≤ 10 nM and VEGF receptor-1 with 1C50≤ 10 nM and PDGFR with 1C50≤ 100 nM.

EFFECT: invention provides strong antiangiogenic effectiveness, ensured avoiding visual acuity loss related to ocular neovascularisation.

7 cl, 5 tbl, 8 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology. The invention discloses an ophthalmic composition containing ketotifen and a hydrogen peroxide source supplying hydrogen peroxide in the amount approximately from 0.001 to approximately 0.1% (wt %) with pH making 4 to 5.3. What is also disclosed is a method of treating and preventing allergic conjunctivitis with using said composition.

EFFECT: invention provides minimum adverse side effects in treating and preventing conjunctivitis.

16 cl, 4 tbl, 1 ex

Eye drops // 2443416

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular ophthalmology. Eye drops have a formulation as follows (g/l): timolol maleate (timolol basis) 1.0-6.0; disodium hydrogen phosphate 5.5-16.5; sodium dihydrogen phosphate 0.8-1.5; sodium chloride 2.0-6.0; ethylenediaminetetraacetatic acid disodium salt 0.1-0.5; benzalkonium chloride 0.03-0.1; polyvinylpyrrolidone 1-100, hydroxypropyl methylcellulose 1.0-5.0, water for injections - to 1 l. The viscosity values range within 5 to 20 mPa·s.

EFFECT: invention provides higher viscosity of the eye drops thereby enabling drug prolongation, as well as promotes cornea moistening and causes no irritant action on eye tissues, has long manufacturing and storage stability of the properties.

1 tbl, 4 ex

FIELD: ophthalmology.

SUBSTANCE: main composition contains: (a) ketotifen fumarate to the concentration in calculation to free ketotifen from approx. 0.01 mas. % to approx. 0.1 mas.%;(b) source of hydrogen peroxide ensuring presence of hydrogen peroxide with trace quantities amounting from approximately 0.001 to approximately 0.1% (mas./vol.); (c) one or several stabilizers of hydrogen peroxide compatible with eyes; (d) hypromellose to the concentration from approximately 0.005 mas% to approximately 0.5 mas.%; and (e) sodium carboxymethyl cellulose to the concentration from approx. 0.005 mas.% to approx 0.5 mas.%. At this the value of composition pH amounts to approximately from 4.0 to 5.3.

EFFECT: invention is a method of treatment and prevention of allergic conjunctivitis which is ensured with application locally in the effective quantity of the mentioned eye composition to person with allergic conjunctivitis or sensitive to it.

13 cl, 15 tbl, 4 ex

FIELD: ophthalmology.

SUBSTANCE: invention is a medicine representing the exciter of neurite genesis of eye tissue, use of the stimulator and method of neurite genesis stimulation. The medicine for eye tissue neurite genesis contains N-(1-acetylpiperidine-4-yl)-4-fluorbenzamide or its pharmaceutically applicable salt and medicine for neurite genesis stimulation of cornea and retina containing N-(1-acetylpiperidine-4-yl)-4-fluorbenzamide or its pharmaceutically applicable salt. The method of neurite genesis stimulation of eye tissue, retina neurite genesis includes insertion of effective quantity of N-(1-acetylpiperidine-4-yl)-4-fluorbenzamide or its pharmaceutically applicable salt into subject who in need of eye tissue neurite genesis.

EFFECT: invention allows improving sensibility of retina, improves treatment of Ocular surface disease, disease of retina epithelium, eye disfunction.

15 cl, 1 tbl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and is applicable in treating patient with ingrown nails. A method implies applying on an involved part of nail a bandage with an ointment of the following formulation: crystalline iodine 5 g, 20% aqueous calcium iodide 10 ml, salicylic acid 10 g, dimexide 28 ml and lanolin 60 g. Then the ingrown part of nail is dissected with a lateral wall along an ingrowth line with a nail plate and deep tissues being cut to a nail bed base and further in a proximal direction. The nail bed is excised with a growth zone using a sharp instrument in a single incision ('movement)'. The en bloc removal of the part of nail with the bed, growth zone and wall is followed by treating a wound surface with 3% hydrogen peroxide. Then 2-4 oblique sutures are applied on the wound, and the lateral wall is created. When applying the sutures within the growth zone, a needle after skin puncture is delivered above the matrix and the nail plate. Starting from the following postoperative day, within a dressing procedure the treated and dried wound is exposed to EHF radiation generated by the AMFIT apparatus of the noise power spectrum of 53.57-78.33 GHz, radiation power 1.0-1.2 mcWt. When radiated, the wound is covered with a sterile tissue for 25-30 minutes once a day for 7 days.

EFFECT: method reduces the length of postoperative treatment and patients' disability, prevents purulent complications and recurrences.

2 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to neurosurgery, traumatology and surgery and is intended for surgical treatment of decubital wounds in case of separation of adjacent tissues in patients with consequences of spinal cord trauma. Cavity of decubital wound is densely tamponed with turunda preliminarily soaked in solution of methylene blue and 3% hydrogen peroxide with ratio of ingredients in solution 9:1. Entrance gate of decubital wound is tightly sewn with interrupted sutures. On skin, transversely to gluteal fold projection, marked is cut of ellipsoid shape sufficient for excision of bedsore capsule, with which sewn entrance gate of decubital wound are located inside excised skin section. Skin cut is performed. Pathologic focus is ablated in one block, guided by size of tamponed cavity and stained tissues. "Blind" draining of operation wound with further plasty of skin-muscular flap is performed. Antibacterial therapy is carried out for 5 days. Drainage is removed after 3 days.

EFFECT: method makes it possible to achieve complete and quality excision of decubital wound, reduce probability of recurrent surgery due to application of methylene blue and 3% hydrogen peroxide, extending narrow ways and slit recesses for complete staining and converting surgery from type of "purulent" into type of "clean" ones.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to conservative surgery, and can be used for treatment of trophic ulcers. For this purpose, introduced are subtilisin-based medication, neurometabolic protector and antibacterial medication with simultaneous cleaning of ulcer from purulo-necrotic coat with 3% solution of hydrogen peroxide and application of bandage based on Hydrofibre and silver ions on ulcer surface, after appearance of granulations applied is medication based on bioplastic collagen material until complete healing of ulcer defect takes place.

EFFECT: method makes possible to reduce terms and increase treatment quality due to achievement of stable therapeutic effect and increase of remission terms.

3 cl, 1 ex

FIELD: medicine.

SUBSTANCE: claimed method relates to medicine, namely to experimental and clinical medicine, and deals with treatment of malignant brain tumours in experiment. For this purpose ozonised physiological solution (OPS) is introduced in intracarotid way with additional introduction of chemiosensitiser, OPS and chemiosensitiser being introduced before chemical preparation successively.

EFFECT: method ensures increase of treatment efficiency with absence of complications due to synergic action of OPS, which increases tumour oxygenation and stimulates in it prooxidant process, and chemiosensitiser, which in conditions of increased oxygen tension acquires anti-tumour properties.

2 tbl, 3 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to therapy, pediatrics, threpsology. It involves clinical and laboratory examination, a subject is finger skin. Nail bones of three fingers are coated simultaneously with 7.5 % aqueous hydrogen peroxide on a palmar surface. A physiologically optimum availability is indicated by no skin albication; lower normal level decrease of availability presents single albication points; selenium deficiency is shown by merged albication regions taking a greater portion of the coated surface.

EFFECT: method allows screening examination of population.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to physiotherapy. The method involves treatment both paravertebrally and within affected greater joints of legs. Paravertebrally, extensor of the back is treated with vibromassage. Vibromassage is applied at frequency 40 Hz, for 2-3 minutes, from both sides simultaneously. Point vibromassage covers a projection of facet joints of vertebras L4-S 1 for 30 seconds on each of 6 points. It is followed with regional vibromassage of an area of affected leg joints. 20 - 30 minutes later, vibromassage is followed with the introduction of an ozone-oxygen mixture at ozone concentration 5 mg/l. The ozone-oxygen mixture is introduced in 4 - 6 symmetric paravertebral points at level L4-S1 and in 4 - 6 periarticular points within the affected leg joints.

EFFECT: method reduces length of treatment and provides prolonged remission.

1 dwg, 4 tbl

FIELD: medicine.

SUBSTANCE: invention discovers the application of a liquid composition for preparing a drug for open wounds and burns. The composition contains a component specified in the salts containing An+ cations and anions formed by halogen oxides according to general formula [OmX] - where A represents lithium, sodium, potassium or calcium, X represents halogen atom, m=1, n=1 or 2, a component specified in the oxygen donors, and a liquid binding agent. In addition, the composition can contain a stabilising agent for the oxygen donors. Said composition promotes tissue cell growth in a wound, thereby providing better tissue regeneration and wound healing.

EFFECT: invention also concerns a wound bandage containing said composition.

28 cl, 3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and biology, more specifically to technology and methods for recovery of leukaemia cell suspension from spleens of high-leukaemia mice, and can be used in experimental oncological haematology for storage of low-frequent subtypes of murine leukaemia. There is offered a method for preparing a leukaemia cell suspension from spleens of inbred mice AKR/JY involving skin preparation with an antiseptic, splenectomy, decapsulation and homogenisation of spleen, filtration of the prepared suspension to be diluted in a sterile cooled artificial extracellular medium to the required concentration of leukaemia cells, prepackaging of the prepared suspension in ampoules for storage and transportation with decapsulation, grinding and homogenisation of fragmented spleen pulp performed in polyglucin solution containing ozone 25.72 mg/l and cooled to 24.0±1.0°C, leukaemia cells are filtered and diluted in polyglucin solution containing ozone 25.72 mg/l and cooled to 15.0±2.0°C.

EFFECT: invention provides maximum safety of specific functional adequacy of the transplanted leukaemia cells.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention is related to composition containing water-swellable, water-insoluble polymer, mixed hydrophilic polymer and complementary oligomer capable to form hydrogen bridges and electrostatic couplings with said hydrophilic polymer, and a substrate. The invention is also applied to the method for teeth wigthening.

EFFECT: tooth hypersensitisation minimal or not observed.

58 cl, 3 ex

FIELD: medicine.

SUBSTANCE: present invention concerns therapeutic compositions for treating skin diseases, such as wounds, abrasions, ulcers, burns, infections, irritations, microbial, mud and water exposures, psoriasis, acne, scars, age spots, sclerosis and other physical or chemical damages, which contain cationic organosilane quaternary ammonium compounds and hydrogen peroxide in the aqueous medium.

EFFECT: invention also concerns the methods of therapeutic purification and skin treatment with said compositions.

35 cl, 5 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions refers to veterinary virology and concerns a peptide-like compound showing the antiviral properties, and also a method for preparing it. That is ensured by synthesis at 22°C for 24 h and molar ratio of the following components: 1,12-dodecanediamine - ethyldiisopropylamine - N-hydroxysuccine imide ester N"б", NIm-di-tert-butyloxycarbonyl-L-histidine 2.3: 5.1: 5.1 in ethylacetate as a solvent, N, N-dimethylethylene diamine added to a reaction mixture (1 mole, 110 mcl) and mixed for 30 min, then sequentially washed out in 2 % citric acid (20 ml), water (20 ml), saturated solution NaHCO3 (20 ml) and water (20 ml); the solvent is removed in vacuum, by dissolving the rest of the mixture "ТФУ":CH2Cl2=1:1 (5 ml); the reaction mixture is kept for 1 h at room temperature, protective groups are removed by trifluoroacetic acid in vacuum, and the rest is boiled off with ethanol (3×10 ml).

EFFECT: peptide-like compound allows extending the range of antiviral agents for treating and preventing cattle viral diseases with reliable reduction of virus reproductions due to stability of the chemical compound and preserved antiviral activity for 2 years.

2 cl, 3 tbl, 5 ex

Up!